MolProbity Ramachandran analysis

MolProbity Ramachandran analysis
2E9W, model 1
General case
180
Isoleucine and valine
180
BA 367
ASN
B421
382LEU
LEU
A 242 VAL
A 106 SER
BA 202
471LEU
LYS
Psi
0
BD 464
42 SER
HIS
D 100 LYS
296PHE
PHE
A B296
B 135 ARG
B 295 THR
D 122
14 ASP
B
ARG
D 11 ASN
122
ARG
AAD178
24ALA
LYS
A 24
89 LYS
ALA
C
A 496 ASP
B 175
A 175
VALVAL
Psi
A 279 SER
B 469 PHE
A 135 ARG
B 267
PHE
D
95 SER
B 352 ASN
A 352 ASN
D 87 VAL
0
B 238 VAL
D 45 ILE
C 45 ILE
A 464 SER
C 67 SER
B 422 VAL
B 70 ILE
B 325 VAL
421 SER
LEU
AB 285
-180
-180
0
Phi
180
Pre-proline
180
A 422 VAL
-180
-180
0
Phi
180
Glycine
180
A 443 CYS
B 443 CYS
Psi
Psi
0
0
D 35 GLY
C 35 GLY
B 466 GLY
A 387 GLY
A 154 LYS
-180
-180
0
-180
Phi
180
Trans proline
180
-180
0
180
Phi
180
Cis proline
180
D 105 PRO
A 413 PRO
Phi
A 456 PRO
A 155 PRO
B 456 PRO
Psi
Psi
0
0
B 166 PRO
C
D 40
40 PRO
PRO
B 468 PRO
-180
-180
-180
0
78.2% (920/1177) of all residues were in favored (98%) regions.
B 238 VAL (-40.3, -17.1)
94.9% (1117/1177) of all residues were in allowed (>99.8%) regions.
were 60 outliers (phi, psi):
89 ALA (-45.6, -12.9)
106 SER (173.6, 133.3)
122 ARG (-52.9, 4.6)
135 ARG (-64.9, 68.9)
154 LYS (-54.1, -174.9)
155 PRO (-119.5, 149.8)
B
B
B
B
B
B
B
B
B
267 PHE (31.2, 41.1)
295 THR (-51.7, 39.9)
296 PHE (-171.8, -27.8)
325 VAL (-151.5, -155.3)
352 ASN (35.6, 26.5)
367 ASN (-51.7, 171.4)
382 LEU (-40.6, 163.4)
421 LEU (-56.9, -172.5)
422 VAL (-74.2, -101.1)
A
A
A
A
A
A
A
A
A
175 VAL (-21.6, 113.8)
178 ALA (-58.0, 2.4)
242 VAL (-50.3, 179.3)
279 SER (54.4, 87.7)
285 SER (-59.6, -176.1)
296 PHE (-179.0, -31.1)
352 ASN (39.1, 14.6)
387 GLY (-60.2, -153.5)
413 PRO (-40.4, 158.3)
B
B
B
B
B
B
C
C
C
443 CYS (-30.0, 142.0)
456 PRO (159.9, 133.7)
464 SER (-177.1, -0.7)
466 GLY (-10.5, -111.6)
468 PRO (-73.4, -147.7)
469 PHE (-54.0, 79.5)
24 LYS (-45.4, -14.8)
35 GLY (45.2, 7.1)
40 PRO (-84.6, -116.9)
A
A
A
A
A
A
A
B
421 LEU (-49.1, 166.8)
422 VAL (-63.7, -153.5)
443 CYS (-34.7, 150.0)
456 PRO (167.9, 151.5)
464 SER (168.9, -55.6)
471 LYS (-18.6, 113.5)
496 ASP (-37.1, -26.3)
70 ILE (-115.1, -119.8)
C
C
D
D
D
D
D
D
45 ILE (-14.2, -56.8)
67 SER (-56.3, -82.8)
11 ASN (-64.2, 13.3)
14 ASP (-69.5, 26.6)
24 LYS (-46.8, -0.2)
35 GLY (37.9, 19.0)
40 PRO (-84.5, -121.4)
42 HIS (-175.2, -0.5)
B
B
B
B
B
122 ARG (-70.7, 23.5)
135 ARG (-54.9, 51.5)
166 PRO (-48.6, -1.6)
175 VAL (-37.3, 113.6)
202 LEU (-20.2, 117.7)
D
D
D
D
D
45 ILE (-31.2, -49.8)
87 VAL (-63.2, 21.5)
95 SER (29.3, 40.3)
100 LYS (-162.2, -12.8)
105 PRO (-41.8, 166.1)
There
A
A
A
A
A
A
http://kinemage.biochem.duke.edu
Phi
180
-180
0
Lovell, Davis, et al. Proteins 50:437 (2003)